BioRestorative Therapies' combined Management Team, Board of Directors and Scientific Advisory Board members have extensive experience in the healthcare industry. Together we have expert experience in the stem cell science, medical-related services, life science services marketing, public company business management and financing, IP development and licensing, business acquisitions, and strategic partnering.
Mark Weinreb is an early pioneer in the field of regenerative medicine and cellular therapy and has significant experience in running public companies. He has served as our Chief Executive Officer since October 2010, as our President since February 2012, and as our Chairman of the Board since April 2011.
From February 2003 to January 2006 he served as the Chief Executive Officer and Chairman of the Board of Directors of Phase III Medical, Inc. where he orchestrated the acquisition of NS California, an adult stem cell collection company that became NeoStem, Inc. (NASDAQ: NBS), a public international biopharmaceutical company engaged in, among other things, adult stem cell-related science. From June 2006 through October 2009, Mr. Weinreb served as President and a director of NeoStem.
In 1976, Mr. Weinreb joined Bio Health Laboratories, Inc., a state-of-the-art medical diagnostic laboratory providing clinical testing services for physicians, hospitals, and other medical laboratories. He became the laboratory administrator in 1978 and then an owner and the laboratory’s Chief Operating Officer in 1982. In such capacity, he oversaw all technical and business facets, including finance and laboratory science technology.
In 1992, Mr. Weinreb founded Big City Bagels, Inc., a national chain of franchised upscale bagel bakeries and became its Chairman and Chief Executive Officer. Big City Bagels went public in 1995, and in 1999 Mr. Weinreb redirected the company and completed a merger with an Internet service provider.
From 2000 to 2002, Mr. Weinreb served as Chief Executive Officer of Jestertek, Inc., a software development company pioneering gesture recognition and control using advanced interactive proprietary video technology.
Mr. Weinreb received a Bachelor of Arts degree in 1975 from Northwestern University and a Master of Science degree in 1982 in Medical Biology from C.W. Post, Long Island University.
Mandy Clyde has been our Vice President of Operations since August 2009. She has served as our Corporate Secretary since December 2010 and served on our Board from September 2010 to April 2011.
From 2006 to 2009, Mrs. Clyde served as Educational Envoy and then CME/CE Coordinator for Professional Resources in Management Education, an accredited provider of continuing medical education. She conducted needs assessments nationally to determine in which areas clinicians most needed current education. She also oversaw onsite educational meetings and analyzed data for outcomes reporting.
From 2005 to 2006, Mrs. Clyde served as surgical coordinator for Eye Surgery Associates and the Rand Eye Institute, two prominent physician practices in Florida. Mrs. Clyde has experience in medical editing for educational programs and is a published author of advanced scientific and clinical content on topics including Alzheimer’s disease, breast cancer, sleep apnea and adult learning. She received a degree in Biology from Mercyhurst College.
Francisco Silva joined BRT in April 2011. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs.
From 2007 to 2011, Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences LLC, companies engaged in the commercialization of human-based biologics for both research and therapeutic applications.
From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms.
Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research.
Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.
Edward Field joined BioRestorative Therapies in February 2015 as President of its brtxDISC™ division. Mr. Field has over 20 years of senior leadership experience in the biotechnology industry with particular expertise in the development and commercialization of cell-based therapies and regenerative medicine products.
Previously, Mr Field served as the Executive Vice President and COO of Cytomedix, Inc. (now Nuo Therapeutics, OTCBB:NUOT) from 2012 to 2014. Mr. Field had been the President and COO of Aldagen, Inc. from 2004 to 2012 prior to its acquisition by Cytomedix in 2012. During this timeframe, Mr. Field was responsible for leading the advancement of eight cell therapy programs into early and late-stage clinical development. Mr. Field also led the building of a Phase 1/2 and a commercial cell therapy manufacturing facility. Additionally, Mr. Field led global commercial operations to support devices sold in the wound care and orthopedic market. During this timeframe, he was also involved in the regulatory efforts for 8 IND clearances, an SPA agreement, Orphan Drug Designation and two potency assays accepted for Phase 3 programs.
Previously, Mr. Field was the President/CEO of two biotechnology companies focused on the development of therapeutics in the cardiovascular, cancer and respiratory diseases areas.
Mr. Field was one of the founding members of the Alliance for Regenerative Medicine. Mr. Field served as the past Vice Chairman and Treasurer of the Alliance for Regenerative Medicine. He has also served as the Chair of its Regulatory and Reimbursement Committee and its Capital Formation Committee.
Mr. Field obtained his MBA from the Colgate Darden School of Business Administration at The University of Virginia in Charlottesville, Virginia and his B.A. from Duke University in Durham, North Carolina.
Robert Paccasassi joined BioRestorative Therapies in September 2015 and holds the title of Vice President, Quality and Compliance. Mr. Paccasassi has over 20 years of experience in highly regulated product operations, with specific expertise in GMP (large and small molecule) clinical and commercial quality assurance and regulatory compliance leadership roles.
Prior to joining Biorestorative Therapies, Mr. Paccasassi was the Corporate Director of Quality Systems (GMP) at Merck KGaA (Darmstadt, Germany), the oldest pharmaceutical and chemical company in the world with over 50,000 employees and operations in 66 countries worldwide. Within this role, Mr. Paccasassi was responsible for leading the ongoing development and implementation of the Corporate Quality Unit’s global GMP policies, processes, directives and operational improvement initiatives.
Prior to his role at Merck KGaA, Mr. Paccasassi held key quality and compliance management roles at EMD Serono, Biogen Idec, Millennium Pharmaceuticals and Regeneron Pharmaceuticals. He previously managed site build-out and operations in Rhode Island and Massachusetts for biotechnology firm, Curative Health Services, and began his career as a Clinical Laboratory Scientist in the field of Immunohematology at Brigham & Woman’s Hospital (Boston, MA). Mr. Paccasassi holds a Master’s degree in Business Administration (MBA) from Johnson & Wales University and a Bachelor of Science degree in Clinical Laboratory Science / Biology from the University of Rhode Island.